Levonorgestrel 52 mg intrauterine system (Levosert®)/Liletta®) in contraception: a profile of its use-Reference-Cited by-同舟云学术

Levonorgestrel 52 mg intrauterine system (Levosert®)/Liletta®) in contraception: a profile of its use

Published:2020-11-05 Issue:12 Volume:36 Page:539-546
ISSN:1172-0360
Container-title:Drugs & Therapy Perspectives
language:en
Short-container-title:Drugs Ther Perspect

Author:

Lyseng-Williamson Katherine A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40267-020-00794-y.pdf

Reference37 articles.

1. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/ Center for Communication Programs (CCP), Knowledge for Health Project. Family planning: a global handbook for providers (3rd ed). Baltimore and Geneva: CCP and WHO, 2018.

2. Levosert 20 micrograms/24 hours intrauterine delivery system (levonorgestrel): EU summary of product characteristics. Budapest: Gedeon Richter Plc.; 2020.

3. Liletta® (levonorgestrel-releasing intrauterine system): US prescribing Information. Irvine/San Francisco: Allergan/Medicines360; 2020.

4. Mirena 52 mg intrauterine delivery system: summary of product characterisitics. Dublin: Bayer Limited; 2018.

5. Mirena (levonorgestrel 52 mg intrauterine device): US prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of two levonorgestrel-releasing intrauterine systems for the treatment of heavy menstrual bleeding: a randomised, controlled, phase 3 trial;The European Journal of Contraception & Reproductive Health Care;2021-06-28